


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): Use of an A method of treating or preventing at least one disease, in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I')



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof and pharmaceutically active derivatives thereof, wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;

Cy' is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 or 1;

R₁ and R₂ are independently from each other selected from the group consisting of hydrogen [[or]] and C₁-C₆-alkyl;

R₃ is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl; C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl,


C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl;

R⁴ and R⁵ are independently from each other selected from the group consisting of H, hydroxy, fluoro, C₁-C₆ alkyl, carboxy, C₁-C₆ alkoxy, C₁-C₃ alkyl carboxy, C₂-C₃ alkenyl carboxy, and C₂-C₃ alkynyl carboxy, whereby wherein at least one of R⁴ or R⁵ is neither a hydrogen nor a C₁-C₆ alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease

for the preparation of a medicament for the treatment and/or prevention of an inflammatory disease or a metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

Claim 2 (Currently Amended): Use of an A method of treating or preventing at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, and polycystic ovary syndrome, comprising

administering at least one alkynyl aryl carboxamide of Formula (I) according to claim 1:



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof and pharmaceutically active derivatives thereof, wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;

n is 0 or 1;

R¹ and R² are independently from each other selected from the group consisting of hydrogen [[or]] and C₁-C₆-alkyl;


R³ is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl;

R⁴ and R⁵ are each independently from each other selected from the group consisting of H, hydroxy, C₁-C₆ alkyl, carboxy, C₁-C₆ alkoxy, C₁-C₃ alkyl carboxy, C₂-C₃ alkenyl carboxy, C₂-C₃ alkynyl carboxy, and amino, or R⁴ and R⁵ may form an unsaturated or saturated heterocyclic ring, whereby wherein at least one of R⁴ or R⁵ is not a hydrogen or C₁-C₆ alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease

for the preparation of a medicament for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

Claim 3 (Currently Amended): A method of treating or preventing at least one disease in a mammal in need thereof, wherein the at least one disease is selected from the group consisting of metabolic disorders mediated by insulin resistance or hyperglycemia, inflammatory diseases, and combinations thereof, comprising

Use of an alkynyl aryl carboxamide according to claim 1 or claim 2 administering at least one alkynyl aryl carboxamide of Formula (I')



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;

Cy' is an aryl, which may optionally be fused by a 3-8 membered cycloalkyl;

n is 0 or 1;

R₁ and R₂ are independently from each other selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R₃ is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl carboxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl; C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl;

R^4 and R^5 are independently from each other selected from the group consisting of H, hydroxy, fluoro, C₁-C₆ alkyl, carboxy, C₁-C₆ alkoxy, C₁-C₃ alkyl carboxy, C₂-C₃ alkenyl carboxy, and C₂-C₃ alkynyl carboxy, wherein at least one of R^4 or R^5 is neither a hydrogen nor a C₁-C₆ alkyl; to the mammal in an amount sufficient to treat or prevent the at least one disease

~~for the preparation of a medicament for the treatment and/or prevention of diabetes type II, obesity or for appetite regulation.~~

Claim 4 (Currently Amended): The method of claim 1, wherein the method is a method of treating Use of an alkynyl aryl carboxamide according to claim 1 or 3 for the preparation of a medicament for the treatment and/or prevention of an inflammatory disease.

Claim 5 (Currently Amended): The method of claim 2, wherein the method is a method of treating Use of an alkynyl aryl carboxamide according to claim 1 to 4 for the preparation of a pharmaceutical composition for the modulation of the activity of PTPs.

Claim 6 (Currently Amended): The method of claim 3, wherein the method is a method of treating Use according to claim 5 wherein the PTP is PTP1B.


Claims 7-8 (Canceled).

Claim 9 (Currently Amended): Use according to any The method of claim 1 claims 1 to 8, wherein R¹ and R² are each H.

Claim 10 (Currently Amended): The method of claim 1, Use according to any of claims 1 to 9, wherein Cy is a phenyl group.

Claim 11 (Currently Amended): Use according to any of claims 1 to 8 The method of claim 1, wherein A is a moiety of the formula -C≡C-R⁶, and wherein R⁶ is C₆-C₁₂ alkyl, a 3-8 membered cycloalkyl, C₁-C₆ alkyl-(3-8 membered) cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₁₂ alkyl phenyl, C₂-C₆-alkenyl phenyl, or a C₂-C₆-alkynyl phenyl.

Claim 12 (Currently Amended): An alkynyl aryl carboxamide or its salt according to any of formulae (Ia), (Ib), (Ic) or (If):



wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;


n is 0 or 1;

R¹ and R² are independently from each other selected from the group consisting of hydrogen [[or]] and C₁-C₆-alkyl; and wherein

R³ is selected from the group consisting of H, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl,

C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl.

Claim 13 (Currently Amended): An alkynyl aryl carboxamide or its salt according to claim 12 having the formula (Ib)[[.]]



wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or a heterocycle group;



n is 0 or 1;

R¹ and R² are independently from each other is selected from the group consisting of hydrogen and C₁-C₆-alkyl; and wherein

R³ is selected from the group consisting of H, hydroxy, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl,

C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl.

Claim 14 (Currently Amended): An alkynyl aryl carboxamide or its salt according to any of formulae (Id) or (Ie):



wherein

A is a C₂-C₁₅ alkynyl, C₂-C₆-alkynyl aryl, or C₂-C₆-alkynyl heteroaryl;

Cy is an aryl, heteroaryl, a 3-8 membered cycloalkyl or heterocycle group;

n is 0 or 1;

R¹ and R² are independently from each other selected from the group consisting of hydrogen [[or]] and C₁-C₆-alkyl;

R³ is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₁-C₆-alkyl amine, C₁-C₆-alkyl alkoxy, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C₁-C₆-alkyl aryl, C₁-C₆-alkyl heteroaryl, C₂-C₆-alkenyl aryl, C₂-C₆-alkenyl heteroaryl, C₂-C₆-alkynyl aryl, C₂-C₆-alkynyl heteroaryl, C₁-C₆-alkyl cycloalkyl, C₁-C₆-alkyl heterocycloalkyl, C₂-C₆-alkenyl cycloalkyl, C₂-C₆-alkenyl heterocycloalkyl, C₂-C₆-alkynyl cycloalkyl, and C₂-C₆-alkynyl heterocycloalkyl.

Claim 15 (Currently Amended): [[An]] The alkynyl aryl carboxamide or its salt according to any of claims 12 or 14 claim 12, wherein R¹ and R² are each H, Cy is a phenyl group, and A is a moiety of the formula -C≡C-R⁶; wherein R⁶ is C₆-C₁₂ alkyl, a 3-8 membered cycloalkyl, C₁-C₆ alkyl-(3-8 membered) cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₁₂ alkyl phenyl, C₂-C₆-alkenyl phenyl, or C₂-C₆-alkynyl phenyl.

Claim 16 (Currently Amended): [[An]] The alkynyl aryl carboxamide or its salt according to any of claims 12 to 15 claim 12, selected from the group consisting of:

5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid

5-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid

5-[(4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[Acetyl(4-dec-1-ynylbenzyl)amino]-2-hydroxybenzoic acid

5-[(4-Dec-1-ynylbenzyl)(pyridin-3-ylcarbonyl)amino]-2-hydroxybenzoic acid

5-[(4-Dec-1-ynylbenzyl)(isonicotinoyl)amino]-2-hydroxybenzoic acid

5-((4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)-2-hydroxybenzoic acid

5-[(4-Dec-1-ynylbenzyl)(thien-2-ylacetyl)amino]-2-hydroxybenzoic acid

5-((4-Dec-1-ynylbenzyl) { (2E)-3-[3-(trifluoromethyl)phenyl]prop-2-enoyl } amino)-2-hydroxybenzoic acid

5-[(4-Dec-1-ynylbenzyl)(phenoxyacetyl)amino]-2-hydroxybenzoic acid

[4-((4-Dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)methyl]phenoxy]acetic acid

(4-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl)phenoxy)acetic acid

(4-[(4-Dec-1-ynylbenzyl)(hexanoyl)amino]methyl)phenoxy)acetic acid

(4-[(Acetyl(4-dec-1-ynylbenzyl)amino)methyl]phenoxy)acetic acid

2-(Carboxymethoxy)-5-((4-dec-1-ynylbenzyl)[(2E)-3-phenylprop-2-enoyl]amino)methyl)benzoic acid

2-(Carboxymethoxy)-5-[(3-cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl)benzoic acid

5-[(Acetyl(4-dec-1-ynylbenzyl)amino)methyl]-2-(carboxymethoxy)benzoic acid

(2E)-3-(4-[(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]methyl)phenyl)acrylic acid

(2E)-3-(4-[(4-Dec-1-ynylbenzyl)(3-phenylpropanoyl)amino]phenyl)acrylic acid
3-(4-[(3-Cyclopentylpropanoyl)(4-dec-1-ynylbenzyl)amino]methyl)phenyl)propanoic acid

5-[(4-[(4-Butylphenyl)ethynyl]benzyl)(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid

5-[(4-[(4-Butylphenyl)ethynyl]benzyl)(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-((4-tert-Butylbenzoyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-((Biphenyl-4-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(2,3-dihydro-1-benzofuran-5-ylcarbonyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(7-carboxyheptanoyl)amino]-2-hydroxybenzoic acid

5-((1,3-Benzodioxol-5-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid

5-[(Benzyloxy)acetyl]{4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(4-hexylbenzoyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(2-naphthoyl)amino]-2-hydroxybenzoic acid
5-((1-Benzothien-2-ylcarbonyl){4-[(4-butylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-{{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]methyl}-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-{{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl}-2-hydroxybenzoic acid

(4- { [{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl)phenoxy)acetic acid, N-methyl-D-glucamine

(4- { [{4-[(4-Butylphenyl)ethynyl]benzyl } (cyanoacetyl)amino]methyl)phenoxy)acetic acid

(4- { [{4-[(4-Butylphenyl)ethynyl]benzyl} (1 H-indazol-3-ylcarbonyl)amino]methyl)-phenoxy)acetic acid

(4- { [{4-[(4-Butylphenyl)ethynyl]benzyl} (pent-4-ynoyl)amino]methyl} phenoxy)-acetic acid

[4-({ {4-[(4-Butylphenyl)ethynyl]benzyl} [(6-hydroxypyridin-3-yl)carbonyl]amino)-methyl)-phenoxy]acetic acid

[4-({ {4-[(4-Butylphenyl)ethynyl]benzyl} [(2-methoxyethoxy)acetyl]amino }methyl)-phenoxy]acetic acid

(4- { [{4-[(4-Butylphenyl)ethynyl]benzyl} (1 H-pyrazol-4-ylcarbonyl)amino]-methyl)phenoxy)acetic acid 3-[(3-Cyclopentylpropanoyl)(4-dec-1-yn-1-ylbenzyl)amino]benzoic acid, N-methyl-D-glucamine

3-[(4-Dec-1-yn-1-ylbenzyl)(hexanoyl)amino]benzoic acid

4- { [{4-[(4-Butylphenyl)ethynyl]benzyl } (3-cyclopentylpropanoyl)amino]methyl)-benzoic acid

4-{{ {4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]methyl}benzoic acid

4-[(4-tert-Butylbenzoyl) { 4-[(4-butylphenyl)ethynyl]benzyl } amino)methyl]benzoic acid

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]benzoic acid

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]benzoic acid

8-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(4-heptylbenzoyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(isoxazol-5-ylcarbonyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(2-thienylacetyl)amino]-2-hydroxybenzoic acid

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-phenylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(4-methoxybenzoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-fluorobenzoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-(acetyl{4-[(4-Chlorophenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Butylphenyl)ethynyl]-2-fluorobenzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

8-((3-Cyclopentylpropanoyl){4-[(4-fluorophenyl)ethynyl]benzyl}amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid, N-methyl-D-glucamine

5-[{6-[(4-Butylphenyl)ethynyl]pyridin-3-yl}methyl](3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

5-[f 4-[(4-Butylphenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3,3-dimethylbutanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine

5-[{4-[(4-Butylphenyl)ethynyl]benzyl}(2-thienylacetyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl} (3,3-dimethylbutanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

3-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-4-fluorobenzoic acid

4-[{4-[(4-Chlorophenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-(Acetyl {4-[(4-butylphenyl)ethynyl]benzyl} amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl} (cyclohexylcarbonyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(hexanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl}(3-cyclopentylpropanoyl)amino]-2-fluorobenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-Butylphenyl)ethynyl]benzyl} (2,2-dimethylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-((3-Cyclopentylpropanoyl) (4-[(4-methoxyphenyl)ethynyl]benzyl)amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-[{4-[(4-tert-Butylphenyl)ethynyl]benzyl} (3-cyclopentylpropanoyl)amino]-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-((3-Cyclopentylpropanoyl) {4-[(4-propoxyphenyl)ethynyl]benzyl }amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine

4-((3-Cyclopentylpropanoyl){4-[(4-propylphenyl)ethynyl]benzyl}amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine, and

4-{(3-Cyclopentylpropanoyl)[4-(5-phenylpent-1-yn-1-yl)benzyl]amino)-2-hydroxybenzoic acid, N-methyl-D-glucamine.

Claim 17 (Currently Amended): A composition comprising at least one [[An]] alkynyl aryl carboxamide of claim 12 or its salt and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof according to any of the claims 10 to 13 for use as a medicament.

Claim 18 (Currently Amended): A pharmaceutical composition containing comprising at least one alkynyl aryl carboxamide of claim 13 or its salt according to any of claims 12 to 15 and a pharmaceutically acceptable carrier, diluent or excipient, or combination thereof.

Claim 19 (Currently Amended): [[A]] The pharmaceutical composition according to of claim 18, further comprising at least one supplementary drug selected from the group consisting of insulin, aldose reductase inhibitors, alpha-glucosidase inhibitors, sulfonyl urea agents, biguanides thiazolidindiones, PPARs agonists, c-Jun Kinase [[or]] and GSK-3 inhibitors.

Claim 20 (Currently Amended): [[A]] The pharmaceutical composition of according to claim 19 wherein said the at least one supplementary drug is selected from the group consisting of a rapid acting insulin, an intermediate acting insulin, a long acting insulin, a combination of intermediate and rapid acting insulins, Minalrestat, Tolrestat, Sorbinil, Methosorbinil, Zopolrestat, Epalrestat, Zenarestat, Imirestat, Ponalrestat, ONO-2235, GP-1447, CT-112, BAL-ARI 8, AD-5467, ZD5522, M-16209, NZ-314, M-79175, SPR-210, ADN 138, [[or]] SNK-860, Miglitol, Acarbose, Glipizide, Glyburide, Chlorpropamide, Tolbutamide, Tolazamide, [[or]] and Glimepiride.

Claim 21 (Currently Amended): A method of preparing [[an]] the alkynyl aryl carboxamide according to any of claims 12 to 15 claim 12, comprising deprotecting, transforming, or deprotecting and transforming the compound of formula (Z) to form the alkynyl aryl carboxamide of formula (I) the de protection and/or transformation step of:



wherein $R^1, R^2, R^3, R^4, R^5, R^{4'}, R^{5'}, n$ and Cy are as above defined and FG is A or a leaving group.

Claims 22-23 (Canceled).

Claim 24 (Currently Amended): An intermediate compound or its salt (II) selected from the group consisting of:

6-[(4-dec-1-ynylbenzyl)amino]-2,2-dimethyl-4H-1,3-benzodioxin-4-one

6-({4-[(4-butylphenyl)ethynyl]benzyl}amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one

Methyl (4- {[(4-dec-1-ynylbenzyl)amino]methyl}phenoxy)acetate

Methyl 5- {[(4-dec-1-ynylbenzyl)amino]methyl}-2-(2-methoxy-2-oxoethoxy)benzoate,
hydrochloride salt

Methyl (2E)-3-(4- {[(4-dec-1-ynylbenzyl)amino]methyl}phenyl)-acrylate

Ethyl (2E)-3- {4-[(4-dec-1-ynylbenzyl)amino]phenyl}acrylate

Methyl 3-(4- {[(4-dec-1-ynylbenzyl)amino]methyl}phenyl)propanoate

7-({4-[(4-Butylphenyl)ethynyl]benzyl}amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one

6-[({4-[(4-Butylphenyl)ethynyl]benzyl}amino)methyl]-2,2-dimethyl-4H-1,3-
benzodioxin-4-one

Methyl 3-[(4-dec-1-yn-1-ylbenzyl)amino]benzoate hydrochloride

Methyl 4-[({4-[(4-butylphenyl)ethynyl]benzyl } amino)methyl]benzoate

Ethyl 4-(14- [(4-butylphenyl)ethynyl]benzyl) amino)benzoate

Methyl 8-({4-[(4-butylphenyl)ethynyl]benzyl }amino)-5,6,7,8-tetrahydronaphthalene-
2-carboxylate

6-({4-[(4-Chlorophenyl)ethynyl]benzyl}amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-
one

4-[(4-Butylphenyl)ethynyl]-2-fluorobenzaldehyde

Methyl 8-({4-[(4-fluorophenyl)ethynyl]benzyl }amino)-5,6,7, 8-tetrahydro-2-
naphthalenecarboxylate

6-[(4-Butylphenyl)ethynyl]nicotinaldehyde

Methyl 5-({4-[(4-butylphenyl)ethynyl]benzyl }amino)-2-fluorobenzoate

Ethyl 3-({4-[(4-butylphenyl)ethynyl]benzyl }amino)-4-fluorobenzoate

7-[((E)- {4-[(4-Chlorophenyl)ethynyl]phenyl}methylidene)amino]-2,2-dimethyl-4H-
1,3-benzodioxin-4-one

Methyl 4-($\{4\text{-[}(\text{4-butylphenyl})\text{ethynyl}]\text{benzyl}\}$ amino)-2-fluorobenzoate; and
7-($\{4\text{-[}(\text{4-Methoxyphenyl})\text{ethynyl}]\text{benzyl}\}$ amino)-2,2-dimethyl-4H-1,3-benzodioxin-4-one.

Claim 25 (New): The method of claim 2, wherein R¹ and R² are each H.

Claim 26 (New): The method of claim 3, wherein R¹ and R² are each H.

Claim 27 (New): The method of claim 2, wherein Cy is a phenyl group.

Claim 28 (New): The method of claim 3, wherein Cy is a phenyl group.

Claim 29 (New): The method of claim 2, wherein A is a moiety of the formula -C≡C-R⁶, and wherein R⁶ is C₆-C₁₂ alkyl, a 3-8 membered cycloalkyl, C₁-C₆ alkyl-(3-8 membered) cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₁₂ alkyl phenyl, C₂-C₆-alkenyl phenyl, or a C₂-C₆-alkynyl phenyl.

Claim 30 (New): The method of claim 3, wherein A is a moiety of the formula -C≡C-R⁶, and wherein R⁶ is C₆-C₁₂ alkyl, a 3-8 membered cycloalkyl, C₁-C₆ alkyl-(3-8 membered) cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, phenyl, C₁-C₁₂ alkyl phenyl, C₂-C₆-alkenyl phenyl, or a C₂-C₆-alkynyl phenyl.